- Home
- CTXR vs ACCS Comparison
CTXR vs ACCS Comparison
Compare CTXR & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTXR | ACCS |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 18.9M |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTXR | ACCS |
|---|---|---|
| Price | $0.58 | $5.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 913.8K | 27.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.38 | ★ 139.36 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $22,619,000.00 |
| Revenue This Year | N/A | $7.40 |
| Revenue Next Year | $147.57 | $8.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.47 | $4.74 |
| 52 Week High | $2.19 | $11.35 |
Technical Indicators
Market Signals| Indicator | CTXR | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 44.85 |
| Support Level | $0.50 | $4.74 |
| Resistance Level | $0.63 | $7.56 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 14.16 | 54.10 |
Price Performance
Historical ComparisonAbout CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.